BIOMARKER:

MAP2K2 mutation

Entrez ID:

Related biomarkers:

‹

›

MAP2K2 mutation MAP2K2 mutation	Melanoma Melanoma	MAP2K2 mutation MAP2K2 mutation	Melanoma Melanoma	CTLA4 inhibitor Sensitive: C3 – Early Trials	CTLA4 inhibitor Sensitive: C3 – Early Trials
MAP2K2 mutation MAP2K2 mutation	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	MAP2K2 mutation MAP2K2 mutation	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	avelumab + binimetinib Sensitive: C3 – Early Trials	avelumab + binimetinib Sensitive: C3 – Early Trials
MAP2K2 mutation MAP2K2 mutation	Melanoma Melanoma	MAP2K2 mutation MAP2K2 mutation	Melanoma Melanoma	dabrafenib Resistant: D – Preclinical	dabrafenib Resistant: D – Preclinical
MAP2K2 mutation MAP2K2 mutation	Melanoma Melanoma	MAP2K2 mutation MAP2K2 mutation	Melanoma Melanoma	trametinib Resistant: D – Preclinical	trametinib Resistant: D – Preclinical